Healthcare
Drugs You Don’t Want To Mix With Marijuana
Here is a list of medications and conditions that are currently thought to have adverse effects when mixed with cannabis.
Marijuana is considered a relatively safe drug, and as time passes medical professionals are finding more and more uses for it as a medicine. From helping those with multiple sclerosis to an FDA approved medical derived from cannabis to treat epilepsy, cannabis is finding its footing and rooting itself firmly in the medical community.
Still, just like with nearly every substance we put in our bodies, there are certain medicines that just don’t mix well with marijuana. What’s more is that while marijuana can have often-desirable effects, these effects can sometimes be dire those with certain medical conditions.
Testing and research is limited, as marijuana is still illegal on a federal level. However, here is a list of medications and conditions that are currently thought to have adverse effects when mixed with cannabis.
Opioids and Sedatives
Opioids and sedatives come with their own risks even when they are not combined with other substances. When they are combined with marijuana, however, their effects can be heightened and amplified, which can be dangerous for those who combine these substances.
“Marijuana’s biggest-known impact is with opioids (for pain), sleep medications, muscle relaxants and alcohol because all affect the central nervous system,” according to Salem Health, which also mentions that when marijuana is used with sedatives and hypnotics it can have an addictive effect.
It is important to be up front and honest with your physician if you are prescribed opioids or sedatives but also want to use marijuana for recreational or medical purposes. At the very least, your physician can recommend some drugs over others or suggest a dosage that will not put your health at risk.

Blood Thinners
Marijuana and blood thinners are another potentially dangerous combination. Marijuana can cause blood thinners to work excessively well, which can have dangerous consequences. “Marijuana can increase the levels of the blood thinner warfarin in the body, which can lead to excessive bleeding,” according to NBC News. Marijuana combined with certain blood thinners can thin your blood out to dangerous levels, so it is imperative you know whether or not the blood thinning drugs you are taking might be affected by marijuana use.
Even if the drugs may not cause severe side effects like excess bleeding, they may otherwise change the drugs effectiveness. ”Using marijuana while on a statin or a blood thinner can change how these drugs work in the body,” lead author Dr. Muthiah Vaduganathan, a cardiologist at the Brigham and Women’s Hospital in Boston, told NBC News.
Anxiety or Depression Medication (SSRIs & Benzodiazepines)
Another group of drugs that can have negative and even dangerous consequences when mixed with marijuana are medications meant to treat anxiety and depression. More specifically, SSRIs (like Cipralex or Prozac) and also Benzodiazepines (like Xanax or Valium) can both have adverse effects when mixed with marijuana.
One reason it is a bad idea to mix these drugs with marijuana is that both types of drug are mood altering. “The challenge for people who have mood disorder or depression is that every time they’re using cannabis, they’re taking another psychoactive drug,” Dr. Timothy Brennan, director of the Addiction Institute at Mount Sinai West and Mount Sinai St. Luke’s Hospitals, told Women’s Health. “And that can make it very challenging for a patient or physician to figure out what drug is actually having an effect on what,” Brennan continued.
This also means that marijuana can potentially negate the positive effects these mood and anxiety medications are having.

Tamoxifen
While medical marijuana is often prescribed to cancer patients undergoing treatment, one medication in particular should never be taken with marijuana. Tamoxifen, which is one drug used to combat breast cancer, may have its benefits negated when combined with marijuana. “If pot interferes with the processing of tamoxifen, it could cause the breast cancer patient to receive little to no benefit from the drug,” Philip Lazarus, a professor of pharmaceutical sciences at Washington State University, told WebMD. This should be a sobering reminder to always consult your physician about your cannabis use when you are on any type of life saving or critical medication.
Continued Challenges With a Lack of Research
While the medications we listed above could be dangerous or pose risks when mixed with marijuana, there still needs to be more research conducted. Unfortunately, even though (as we’ve reported) more people now smoke marijuana than cigarettes in this country, there have been limited trials on how pharmaceuticals interact with marijuana.
“So even while many people may use marijuana, tight federal restrictions limit researchers’ ability to study cannabis as approved medications are typically studied, including evaluating whether it can safely be taken with medications,” according to U.S. News. This is one strong argument as to why there needs to be a reclassification of marijuana. Taking marijuana off the Schedule I drug list would allow for significantly more research on the substance, and would improve how we understand the ways it interacts with other substances in our body.
Source: https://thefreshtoast.com/cannabis/drugs-you-dont-want-to-mix-with-marijuana/
Cannabis & Policy
Supreme Court Raises Concern Over Steep Medicine Mark-Ups at Corporate Hospitals
The Supreme Court of India has questioned the sharp difference between the prices at which medicines reach retailers and the maximum retail prices charged to patients, particularly in corporate hospitals.
During a hearing on September 29, a bench of Justices Vikram Nath and Sandeep Mehta examined whether a uniform limit of 16% could be applied to medicine margins. The discussion followed the court’s earlier concern over a cancer medicine with a retailer price of about ₹2,700–₹3,000 but an MRP of ₹27,000.
Court Questions Wide Gap Between Retail Price and MRP
The Supreme Court focused on how such large differences between the Price to Retailer (PTR) and MRP can affect patients who have little choice over where they obtain medicines during hospital treatment.
The bench questioned why different pricing rules should apply to essential and non-essential medicines and asked whether a common 16% margin could be considered across pharmaceutical products. The issue remains under consideration and the court has not imposed such a cap at this stage.
Concerns Over In-House Hospital Pharmacies
The court also examined the purchasing practices of corporate hospitals.
According to the proceedings, patients admitted to some hospitals may be directed to obtain medicines from the facility’s own pharmacy. The bench raised concerns about situations in which hospitals may not accept medicines purchased from outside pharmacies or may decline to provide treatment assurances when patients bring their own drugs.
The issue becomes particularly significant for patients undergoing expensive or long-term treatments, where medicine costs can represent a substantial part of the overall bill.
Impact on Government Health Schemes
The Supreme Court also highlighted the potential effect of high medicine prices on publicly funded healthcare programmes.
Where treatment is reimbursed under government schemes, the court noted that taxpayers ultimately finance the medical expenses. If reimbursement is calculated using substantially inflated MRPs, the difference between procurement costs and the amount reimbursed could increase public expenditure.
The bench also pointed to a consumer-trust problem. If a medicine officially carries an MRP of ₹27,000 but a pharmacy offers it for around ₹3,000, patients may question whether the cheaper medicine is genuine.
Government Seeks Time to Examine the Issue
Solicitor General Tushar Mehta, appearing for the Centre, told the court that the government would need to work out a balanced approach.
The government has been asked to examine the issue with relevant officials before responding further. The court granted additional time for consultations rather than immediately introducing a new pricing rule.
The proceedings are part of a broader case concerning medicine pricing, generic prescriptions and regulation of medical costs. The Supreme Court’s official website lists Justice Vikram Nath and Justice Sandeep Mehta as sitting together in Court No. 2 on September 29, 2026.
Court’s Earlier Warning on Medicine Pricing
The latest hearing follows strong observations made by the Supreme Court earlier in September after it examined the pricing of cancer medicines.
The bench had highlighted an example where a medicine costing roughly ₹2,700 at the retailer level carried an MRP of ₹27,000. The court questioned how such a substantial price difference could be justified when patients are dependent on life-saving medicines.
The court also heard arguments that pharmaceutical manufacturers may not necessarily retain the entire difference between the retailer price and the final amount charged to patients, with significant margins potentially arising at later stages of the supply chain, including retail and hospital sales.
What Happens Next?
The Supreme Court has not yet ordered a nationwide 16% medicine-margin cap. Instead, it has asked the government to consider possible regulatory solutions and return with its response.
The matter is scheduled for further hearing on October 12, when the court is expected to consider the government’s position on medicine pricing and related issues.
Any eventual regulatory change could have implications for patients, hospitals, pharmacies, pharmaceutical companies and government-funded healthcare programmes. For now, the 16% figure remains a proposal raised during the court proceedings rather than an operative rule.
Economic Fraud
Fugitive Medicare Fraud Suspect Returned to US After Arrest in Türkiye
U.S. federal authorities have secured the return of a fugitive suspect accused of involvement in a massive Medicare fraud operation, following his arrest in Türkiye. The extradition marks a significant development in a major healthcare fraud investigation that allegedly cost the American healthcare system billions of dollars.
The suspect, Ibrahim Khaldoon Hilmi, is now in federal custody after spending more than a year outside the United States. Prosecutors are expected to move forward with criminal proceedings as investigators continue to examine what authorities describe as a sophisticated fraud network targeting public healthcare funds.
International Manhunt Ends with Arrest in Türkiye
According to federal investigators, Hilmi left the United States in May 2025 while authorities were building their case. Law enforcement agencies later tracked his location to Türkiye, where cooperation between U.S. and Turkish officials led to his detention.
Following the completion of legal and diplomatic procedures, the suspect was transferred to American custody. Officials described the operation as a successful example of international law enforcement collaboration in pursuing suspects accused of large-scale financial crimes.
A specialized FBI team reportedly traveled to Türkiye to coordinate the transfer and ensure the extradition process was completed smoothly.
Alleged Scheme Targeted Medicare Reimbursement System
Investigators allege that Hilmi played a central role in a fraudulent operation that exploited the Medicare reimbursement system through false claims and improper billing practices.
Authorities estimate that the alleged scheme involved financial losses equivalent to approximately ₹31,700 crore, making it one of the most significant healthcare fraud investigations in recent years.
While the allegations have yet to be tested in court, investigators believe the operation relied on complex financial transactions and coordinated activities designed to extract funds from a government healthcare program serving millions of beneficiaries.
Federal Agencies Expand Investigation
The case extends beyond a single suspect. Federal authorities are examining the potential involvement of additional individuals, businesses, and organizations believed to be connected to the alleged fraud network.
Investigators are reviewing banking records, financial transactions, corporate structures, and digital evidence to determine the full scope of the operation and identify any additional participants.
Officials indicated that tracing the movement of funds and uncovering potential links between entities remains a key focus of the ongoing investigation.
Healthcare Fraud Remains a Major Concern
Government agencies continue to treat Medicare fraud as a serious threat because it impacts taxpayer-funded healthcare resources intended for legitimate medical services.
Authorities argue that fraudulent claims can divert critical funding, increase administrative costs, and place additional pressure on public healthcare programs. As healthcare systems become increasingly digitized, fraud schemes have also become more sophisticated and difficult to detect.
Financial crime specialists note that modern healthcare fraud investigations often involve shell companies, layered transactions, and cross-border financial networks that require extensive forensic analysis.
Growing Importance of Global Law Enforcement Cooperation
The successful return of Hilmi highlights the increasing role of international cooperation in combating financial crime. Law enforcement agencies worldwide are relying more heavily on cross-border partnerships to locate and apprehend suspects who attempt to evade prosecution by relocating overseas.
Officials say such collaborations are essential as financial crimes become increasingly global in nature, involving multiple jurisdictions and complex international money flows.
Legal Proceedings Ahead
The U.S. Department of Justice is expected to present evidence against the suspect as court proceedings move forward. Prosecutors will seek to establish the extent of the alleged fraud and determine accountability among those involved.
The outcome of the case could influence future enforcement efforts aimed at protecting public healthcare programs and strengthening safeguards against large-scale financial misconduct.
For federal authorities, the extradition of Ibrahim Khaldoon Hilmi represents a major step in an ongoing campaign to crack down on healthcare fraud and recover public funds allegedly lost through criminal schemes.
Cyber Crime
Telangana Doctors Lose Nearly ₹30 Crore to Cyber Fraud Since September 2024
Cybercriminals have defrauded doctors across Telangana of nearly ₹30 crore since September 2024, prompting authorities to strengthen awareness campaigns and cybersecurity education within the healthcare sector.
The alarming figures were revealed during a cyber awareness programme organized by the Telangana Cyber Security Bureau (TGCSB) in Hyderabad. Senior officials warned that healthcare professionals are increasingly becoming targets of sophisticated online scams despite their educational and professional backgrounds.
Healthcare Professionals Under Growing Cyber Threat
Addressing representatives from various medical associations, TGCSB Director Shikha Goel highlighted the rising number of cybercrime incidents involving doctors and healthcare workers. She emphasized that cybercriminals are exploiting digital platforms to target individuals across all professions, including highly qualified medical practitioners.
Officials stressed that vigilance, awareness, and prompt reporting remain the strongest defenses against cyber fraud. The event focused on strengthening cooperation between law enforcement agencies and the medical fraternity to improve preparedness against evolving cyber threats.
More than 70 office-bearers from medical organizations across Telangana attended the session, including presidents, secretaries, treasurers, and senior representatives.
Investment Scams Responsible for Major Financial Losses
According to TGCSB data, at least 735 doctors have reported cybercrime-related incidents since September 2024, with total losses reaching approximately ₹29.88 crore.
Business and investment fraud emerged as the most damaging category, accounting for losses of ₹22.39 crore involving 127 victims. Investigators noted that fraudsters often lure professionals with promises of high returns, fake investment opportunities, and deceptive business schemes.
Authorities also reported a wide range of other cyber offences affecting doctors, including digital arrest scams, identity theft, impersonation fraud, fake advertisements, job-related scams, insurance fraud, cryptocurrency fraud, UPI-related cheating, matrimonial scams, and sextortion cases.
Authorities Stress Importance of Rapid Reporting
The Telangana Cyber Security Bureau urged victims to report cybercrime incidents immediately, especially during the critical “golden hour” after a fraudulent transaction occurs.
Officials explained that timely complaints through the national cybercrime helpline 1930 and the official cybercrime reporting portal can significantly improve the chances of freezing suspicious transactions and recovering stolen funds.
The bureau further warned that cybercriminals are employing increasingly advanced techniques to deceive victims, making awareness and quick action more important than ever.
Medical Associations Join Awareness Drive
Representatives from associations of paediatricians, cardiologists, dentists, orthopaedic surgeons, gynaecologists, and hospital administrators participated in the discussions. The groups pledged to work closely with authorities to spread cybersecurity awareness through hospitals, clinics, medical conferences, and professional training programmes.
Officials believe that expanding cyber awareness among healthcare professionals will play a key role in reducing financial fraud and strengthening digital security across the state’s medical community.
As cyber threats continue to evolve, law enforcement agencies are encouraging doctors and other professionals to remain cautious when responding to investment offers, unknown communications, and requests for sensitive financial information online.
-
Business3 years agoPot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business3 years agoNew Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business3 years agoAlabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business3 years agoWashington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business3 years agoMarijuana companies suing US attorney general in federal prohibition challenge
-
Business3 years agoLegal Marijuana Handed A Nothing Burger From NY State
-
Business3 years agoCan Cannabis Help Seasonal Depression
-
Blogs3 years agoCannabis Art Is Flourishing On Etsy
